<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289337</url>
  </required_header>
  <id_info>
    <org_study_id>CS19052</org_study_id>
    <nct_id>NCT04289337</nct_id>
  </id_info>
  <brief_title>Double-blind Clinical Trials of Probiotic Products in Oral Health.</brief_title>
  <official_title>Double-blind Clinical Trials of Probiotic Products in Oral Health.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glac Biotech Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to evaluate the effects of supplementary probiotics and their metabolites on oral
      environment and oral microbiota, Taiwan FDA No. 88037803 will be used to evaluate the effects
      of oral probiotic candidate strains from previous research results and develop oral probiotic
      products.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Actual">December 6, 2019</completion_date>
  <primary_completion_date type="Actual">December 2, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline colony-forming unit (CFU) of Streptococcus mutans at 4 weeks.</measure>
    <time_frame>4 weeks.</time_frame>
    <description>The plaque on the inside and outside of teeth was collected by cotton swab and putting in the microbial culture broth before and after taking the oral tablets. The microbial culture broth will be diluted and smeared on the mitis salivarius-bacitracin agar (MSBA) plate for counting the CFU of Streptococcus mutans.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline concentration of saliva immunoglobulin A (IgA) at 4 weeks.</measure>
    <time_frame>4 weeks.</time_frame>
    <description>The saliva was collected by the centrifuge tube before and after taking the oral tablets. IgA will be detected by enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline microbiota at 4 weeks.</measure>
    <time_frame>4 weeks.</time_frame>
    <description>The saliva was collected by the next-generation sequencing (NGS) saliva collection tube before and after taking the oral tablets. The changes in microbial flora will be detected by NGS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from baseline CFU of total oral microbiota at 4 weeks.</measure>
    <time_frame>4 weeks.</time_frame>
    <description>The plaque on the inside and outside of teeth was collected by cotton swab and putting in the microbial culture broth before and after taking the oral tablets. The microbial culture broth will be diluted and smeared on the plate count agar (PCA) plate for counting the CFU of total oral microbiota.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline CFU of probiotics at 4 weeks.</measure>
    <time_frame>4 weeks.</time_frame>
    <description>The plaque on the inside and outside of teeth was collected by cotton swab and putting in the microbial culture broth before and after taking the oral tablets. The microbial culture broth will be diluted and smeared on the De Man, Rogosa and Sharpe agar (MRSA) plate for counting the CFU of probiotics.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Probiotics</condition>
  <condition>Oral Health</condition>
  <condition>Probiotic Metabolites</condition>
  <arm_group>
    <arm_group_label>Combined probiotics (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined probiotics (2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined heat-killed probiotics (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined heat-killed probiotics (2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32 and Lactobacillus paracasei ET-66.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic metabolites</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66 metabolites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Does not contain probiotics, heat-killed probiotics and related metabolites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Combined probiotics (1)</intervention_name>
    <description>Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.</description>
    <arm_group_label>Combined probiotics (1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Combined probiotics (2)</intervention_name>
    <description>Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.</description>
    <arm_group_label>Combined probiotics (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Combined heat-killed probiotics (1)</intervention_name>
    <description>Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.</description>
    <arm_group_label>Combined heat-killed probiotics (1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Combined heat-killed probiotics (2)</intervention_name>
    <description>Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.</description>
    <arm_group_label>Combined heat-killed probiotics (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic metabolites</intervention_name>
    <description>Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.</description>
    <arm_group_label>Probiotic metabolites</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between 20 to 40 years old.

          -  More than 10^5 Streptococcus mutans (CFU/mL) of saliva.

        Exclusion Criteria:

          -  Smoking.

          -  Subject has major illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsieh-Hsun Ho, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glac Biotech Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glac Biotech Co., Ltd</name>
      <address>
        <city>Tainan City</city>
        <zip>802</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glac Biotech Co., Ltd</investigator_affiliation>
    <investigator_full_name>Hsieh-Hsun Ho</investigator_full_name>
    <investigator_title>R.D. Manager Doctor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

